ALK抑制剂延长ALK阳性未分化甲状腺癌小鼠模型生存期
研究构建了甲状腺细胞特异性表达ALKF1174L突变并纯合缺失Trp53的小鼠模型,该模型发展为局部侵袭和转移性未分化甲状腺癌(ATC)。体外实验显示ALK抑制剂TAE-684降低AKT和ERK磷酸化并诱导剂量依赖性细胞毒性;体内实验TAE-684组中位生存期显著延长(66天 vs 18天,p<0.0001)。
要点
- ALKF1174L突变联合Trp53缺失可驱动小鼠发生未分化甲状腺癌。
- ALK抑制剂TAE-684在体外抑制AKT和ERK磷酸化并诱导ATC细胞毒性。
- TAE-684显著延长模型小鼠中位生存期(66天 vs 18天,p<0.0001)。
核心结论
- ALKF1174L突变联合Trp53缺失可导致未分化甲状腺癌发生。
- 该研究首次提供功能数据支持ALK抑制剂用于ALK驱动的ATC患者。
研究设计与样本
- 研究使用可诱导甲状腺细胞特异性表达ALKF1174L并纯合缺失Trp53的小鼠模型(Trp53KO/ALKF1174L小鼠)。
- 研究建立了携带ALKF1174L和Trp53KO的原代甲状腺癌细胞系,并进行体外和体内实验。
主要发现
- Trp53KO/ALKF1174L小鼠中位生存期严重缩短,甲状腺显著增大。
- 组织病理学确认小鼠发生局部侵袭和转移性未分化甲状腺癌。
- TAE-684处理原代Trp53KO/ALKF1174L ATC细胞可降低AKT和ERK磷酸化并诱导剂量依赖性细胞毒性。
- TAE-684治疗组小鼠中位生存期显著长于溶剂组(66天 vs 18天,p<0.0001)。
临床怎么用
- 对于ALK驱动的未分化甲状腺癌,ALK抑制剂可能提供生存获益。
- 该小鼠模型和细胞系可用于探索ATC分子特征及测试新疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anaplastic thyroid cancer (ATC) is the most aggressive thyroid cancer with a median survival of less than six months. So far, no therapies offering a survival benefit are established. Thus, new therapeutic approaches are urgently needed. In general, genetic alterations leading to ATC increase PI3K and MAPK/ERK signaling and include mutations in receptor tyrosine kinases and tumor suppressor genes. They often occur together with the loss of p53, the most prevalent mutation in human ATC. Among such alterations are mutations and rearrangements of the anaplastic lymphoma kinase (ALK) gene. METHODS: To study ATC and potential treatment options, we generated a mouse model with inducible thyrocyte-specific expression of constitutively active mutant ALKF1174L and homozygous deletion of Trp53 due to a Cre recombinase under control of the thyroglobulin promoter (thyroglobulin [Tg]-CreERT2+/0;lox-stop-lox (LSL)-ALKF1174L/+;Trp53LoxP/LoxP mice, here referred to as Trp53KO/ALKF1174L mice). Moreover, we established several primary thyroid cancer cell lines harboring ALKF1174L and Trp53KO and investigated the effects of ALK inhibition in vitro and in vivo. RESULTS: Median survival of Trp53KO/ALKF1174L mice was severely reduced, and the mice showed massively enlarged thyroids. Histopathology confirmed the development of locally invasive and metastatic ATC. Treatment of primary Trp53KO/ALKF1174L ATC cells with the ALK inhibitor TAE-684 decreased AKT and ERK phosphorylation and induced a dose-dependent cytotoxicity. Trp53KO/ALKF1174L mice treated with TAE-684 showed significantly extended median survival compared with the solvent group (66 days vs. 18 days, p < 0.0001). CONCLUSIONS: Our data demonstrate that the combination of ALKF1174L mutation with Trp53 loss leads to the development of ATC. This study provides the first functional data supporting the use of ALK inhibitors in patients with ALK-driven ATC. Our novel ATC mouse model and the derived cell lines offer valuable tools to explore the molecular characteristics of ATC, especially signaling pathway activation and tumor microenvironment, and to test novel therapeutics for the treatment of advanced thyroid cancers.
引用
- Machlah YM, Brandenburg T, Hönes GS, et al. ALK Inhibition Prolongs Survival in a Mouse Model of ALK-Positive Anaplastic Thyroid Cancer. Thyroid. 2025. PMID: 41467979. doi:10.1177/10507256251409070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。